Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jul 1;8(4):pkae042.
doi: 10.1093/jncics/pkae042.

Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812

Affiliations
Randomized Controlled Trial

Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812

Julia E McGuinness et al. JNCI Cancer Spectr. .

Abstract

Deep learning-based mammographic evaluations could noninvasively assess response to breast cancer chemoprevention. We evaluated change in a convolutional neural network-based breast cancer risk model applied to mammograms among women enrolled in SWOG S0812, which randomly assigned 208 premenopausal high-risk women to receive oral vitamin D3 20 000 IU weekly or placebo for 12 months. We applied the convolutional neural network model to mammograms collected at baseline (n = 109), 12 months (n = 97), and 24 months (n = 67) and compared changes in convolutional neural network-based risk score between treatment groups. Change in convolutional neural network-based risk score was not statistically significantly different between vitamin D and placebo groups at 12 months (0.005 vs 0.002, P = .875) or at 24 months (0.020 vs 0.001, P = .563). The findings are consistent with the primary analysis of S0812, which did not demonstrate statistically significant changes in mammographic density with vitamin D supplementation compared with placebo. There is an ongoing need to evaluate biomarkers of response to novel breast cancer chemopreventive agents.

PubMed Disclaimer

Conflict of interest statement

J.E. McGuinness reports serving on an advisory board for Gilead Sciences, Inc, and receiving honorarium from OncLive and WebMD.

G.L. Anderson reports receiving other commercial research support from Mars Symbioscience.

B. Arun reports receiving commercial research grant from Abbvie paid to the institution, Invitae nonpaid, and AstraZeneca paid to the institution, and is a consultant/advisory board member for Abbvie steering committee and Bright Pink.

The other authors declared no potential conflicts of interest.

References

    1. Wickerham DL, Costantino JP, Vogel VG, et al. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res. 2009;181:113-119. doi:10.1007/978-3-540-69297-3_12. - DOI - PMC - PubMed
    1. Cuzick J, Sestak I, Cawthorn S, et al.; IBIS-I Investigators. Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67-75. doi:10.1016/s1470-2045(14)71171-4. - DOI - PMC - PubMed
    1. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696-706. doi:10.1158/1940-6207.Capr-10-0076. - DOI - PMC - PubMed
    1. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. New Engl J Med. 2011;364(25):2381-2391. doi:10.1056/NEJMoa1103507. - DOI - PubMed
    1. Cuzick J, Sestak I, Forbes JF, et al. IBIS-II Investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041-1048. doi:10.1016/s0140-6736(13)62292-8. - DOI - PubMed

Publication types